Dublin, Ireland – 23 May 2025: SelekTx, a UCD spin-out project developing a new class of precision biologics for hard-to-drug targets, today announced that Professor David O’Connell presented the company’s innovative GPCR-targeting platform at the leading biologics conferences Protein Engineering Summit Boston on 12 May 2025 and the 4th GPCRs-Targeted Drug Discovery Summit, held on 21 May 2025. The presentations, titled "Targeting the pro-inflammatory activity of the cannabinoid receptor CB2R in IBD using libraries of highly stable, constrained GPCR-modulating peptides" & “Harnessing a Highly-Selective Designer Protein Platform to Identify Agonists, Antagonists & Inverse Agonists for GPCR Targets,” presented data supporting the therapeutic potential of Selektides—SelekTx’s proprietary class of engineered protein binders.
Lund, Sweden and Dublin, Ireland – 2 December 2024: SelekTx, a UCD spin-out project developing a new class of precision biologics targeting hard-to-drug disease proteins, today announced that Professors Sara Linse (Lund University) and David O’Connell (University College Dublin) have been awarded an Industrial Biotechnology and Environmental Biotechnology - Project Grant by the Novo Nordisk Foundation to advance the foundational science underpinning the SelekTx platform.
Basel, Switzerland – 17 October 2024: SelekTx founder, Professor David O’Connell, presented a podium presentation titled ‘Selective Human Receptor Modulating Peptides for GPCR agonism and antagonism’ as invited speaker in the Protein Engineering track where he described the development of the SelekTx drug discovery platform and described how winning recent funding had allowed the establishment of a scientific team to exploit the proprietary libraries of Selektides against the important disease target GPCRs, GLP-1R and CB2R.
Dublin, Ireland – 23 June 2024 – SelekTx, a UCD spin-out project developing a new class of precision biologics targeting hard-to-drug disease proteins, today announced it has been awarded a prestigious Commercialisation Fund grant from Enterprise Ireland. The award will support the development and de-risking of SelekTx’s proprietary drug discovery platform over a two-year period, accelerating the path to spin-out and commercialisation.
Dublin, Ireland & Lund, Sweden — 17 May 2022—SelekTx founders Prof. Sara Linse (Lund University) and Prof. David O’Connell (University College Dublin), together with Dr Pietro Sormanni University of Cambridge, report the discovery of engineered protein binders that selectively inhibit the most toxic step in the amyloid-β (Aβ42) aggregation pathway implicated in Alzheimer’s disease published in Proceedings of the National Academy of Sciences USA (PNAS USA). This basic research lays the foundation for the development of a new class of precision biologic, Selektides, to target difficult-to-drug disease proteins via a new platform drug discovery approach that will be developed by SelekTx, a UCD spin out project.